Neptune has obtained a patent relating to the treatment of Alzheimer’s.
The patent, which is the company’s first to specifically target neurological conditions, is granted for the US market and is valid until 2022. The claims focus on treating Alzheimer’s disease by administering an effective amount of a phospholipid composition, wherein the phospholipid composition comprises DHA and EPA.
“Today’s announcement provides additional strength to our patent estate and highlights our commitment to continue to protect and build this valuable asset for both our nutraceutical and pharmaceutical businesses”, said Henri Harland, president and CEO of Neptune. “Neurological disorders, such as Alzheimer’s, are growing and new methods to prevent and treat such conditions using alternative treatments are continuously being sought out. In addition to Neptune, this new patent substantially benefits our subsidiary, NeuroBioPharm, as it continues to develop omega-3 phospholipid products for neurological pharmaceutical applications.”
